Press Releases and News archive

Xellia Pharmaceuticals appoints Hanne Junggreen as Corporate Vice President of Global Quality

Xellia Pharmaceuticals appoints John Stewart as Senior Vice President of Global Product Supply

Xellia Pharmaceuticals Joins End Drug Shortages Alliance

Xellia Pharmaceuticals secures $430m financing to support long-term growth

Celebrating World Quality Week 2022

Xellia in the news, Berlingske Media Life Science Edition

Xellia Pharmaceuticals Joins the Pharmaceutical Supply Chain Initiative to Promote focus on Responsible Supply Chains and Business Practices

Surviving Sepsis: Importance of Timely Antibiotic Administration – A whitepaper sponsored by Xellia Pharmaceuticals USA LLC

Celebrating Diversity Inclusion & Belonging

The Impact of Pre-mix Intravenous Medication in the Pharmacy - A study by Virginia Mason Institute (VMI) sponsored by Xellia Pharmaceuticals USA LLC

Xellia Pharmaceuticals USA, LLC, Receives Supplier Horizon Award from Premier Inc.

Xellia Pharmaceuticals Reports 2021 Business Update and 2022 Outlook

Xellia Pharmaceuticals Cleveland, Ohio manufacturing facility commercially operational for production of key anti-infective drug products for US hospitals and patients

Xellia Pharmaceuticals globally certified as a Great Place to Work® following company-wide employee survey

Xellia Pharmaceuticals receives Industrial Research and Innovation (IRI) Grant to support the development of Value-Added Medicines (VAM) in the antibiotics space

Celebrating Earth Day 2021!

Xellia in the news, Berlingske Media Life Science Edition - Fighting the Slow Pandemic

Xellia has signed the UN Women’s Empowerment Principles

Xellia Pharmaceuticals appoints Preben Haaning to its Board of Directors

Xellia Pharmaceuticals appoints Patrick Brunner as Vice President North America Manufacturing Operations and new site head at its Cleveland, Ohio facility

Xellia Pharmaceuticals announces a new three-year collaboration agreement with SOS Children’s Villages, Denmark

Xellia Pharmaceuticals joins Medicines for Europe to support better access to critical medicines

SOS Talk: Carl-Åke Carlsson, CEO & President of Xellia Pharmaceuticals, and Marianne Norup-Nielsen, Senior Director Global IT, interviewed on our collaboration with SOS Children’s Villages

Xellia joins World Antimicrobial Awareness Week on 18-24 November 2020

Xellia celebrates World Quality Day on November 12th 2020

Xellia Pharmaceuticals demonstrates commitment to the fight against sepsis by providing support for Sepsis Awareness Month

Podcast: Molecule to Market featuring Carl-Åke Carlsson, CEO & President Xellia Pharmaceuticals

The release of Xellia’s global recruitment film: Our Culture, Our Values, Our Purpose – Being an Xellian | Global | Xellia Pharmaceuticals

Xellia's response to the COVID-19 outbreak

Xellia Pharmaceuticals Opens New Commercial Office in Dubai

Xellia Pharmaceuticals recruiting additional >100 employees to expand workforce at its Cleveland, Ohio manufacturing site

The release of Xellia’s corporate film: Our Journey, Building for the Future.

Xellia Pharmaceuticals Reports Strong Full Year Results for 2019 and Provides Key Business Updates

Xellia Pharmaceuticals' site, Cleveland, Ohio, passes FDA inspection of Injectable Drug Manufacturing Methods, Facilities, Processes & Controls

Xellia's response to the COVID-19 outbreak

Xellia’s response to the COVID-19 outbreak

Xellia Pharmaceuticals appoints Peter Baker as Chief Commercial Officer, Xellia North America

Xellia Pharmaceuticals Divests Raleigh, North Carolina Production Facilities to Sagent Pharmaceuticals

Xellia Pharmaceuticals welcomes HRH Princess Benedikte of Denmark to its Copenhagen Site

Xellia Pharmaceuticals Appoints Barbara Purcell to its Board of Directors

Xellia Pharmaceuticals Opens North American Commercial Office in Chicago

LEUKOCARE and Xellia Pharmaceuticals partner to discover innovative formulations

Xellia Pharmaceuticals Appoints Matthew Anderson as Chief Financial Officer

Xellia Pharmaceuticals Appoints Craig Boyd as President, Xellia US as it Expands its Commercial Organization

Xellia Pharmaceuticals Reports on Strong 2017 Financial Results and Advances in the Development of its Novel Premixed Vancomycin Ready-to-Use (RTU) Bag

Xellia Pharmaceuticals Welcomes VIPs from across Ohio as it prepares for Full Scale Manufacturing and Continues to Hire New Talent

Xellia Pharmaceuticals Expands its Global Specialty Anti-infective Product Manufacturing Capabilities with a US$25m Investment in its Copenhagen Site

The Xellia SOS Children’s Villages’ Medical Center Report

Xellia Pharmaceuticals Completes Expansion of its Budapest Facilities, Strengthening its Global Anti-infective Product Capabilities

Publication in Acquisition International: A Manufacturing 'One-Stop-Shop'

Publication in Pharma Horizon: Five minutes at DCAT with Carl-Åke Carlsson

Publication in Life Science Leader: Why Xellia Revived a Shuttered Pharma

Publication in S&P Global Market Intelligence: Small companies play big role in search for superbug killers

Publication in the Danish magazine Optimering: Xellia's Focus on Energy Consumption

Xellia Pharmaceuticals’ Increased Revenue by 17% in 2016

Xellia Pharmaceuticals Signs Davos Declaration on Combating Antimicrobial Resistance

Xellia Pharmaceuticals Commences Packaging and Distribution Operations at Cleveland Site after Successful FDA Inspection

Xellia Pharmaceuticals Expands Croatian Anti-Infective Product and Innovation Capabilities to Tackle Antimicrobial Resistance Crisis

Xellia Pharmaceuticals Welcomes Dignitaries from Hungarian Ministry of Foreign Affairs and Trade and Hungarian Embassy to Copenhagen Headquarters

Xellia Pharmaceuticals Expands Budapest Facilities to Strengthen Anti-infective Product Capabilities

Xellia Pharmaceuticals Full Year Results for the year ended 31 December 2015

Xellia Pharmaceuticals Reaches Agreement with FDA on Modifications to Consent Decree for Newly-Acquired Cleveland Site

Xellia Pharmaceuticals Expands US Production with Acquisition of Manufacturing Plant from Hikma Pharmaceuticals

Xellia Pharmaceuticals Expands Raleigh, NC Site to Become New North American Headquarters

Xellia Pharmaceuticals Focuses on Innovation in Anti-infectives with Formation of Scientific Advisory Board

On European Antibiotic Awareness Day Xellia Pharmaceuticals Strengthens Commitment to Innovation in Anti-Infectives with New API R&D Center of Excellence in Oslo

Xellia Pharmaceuticals Welcomes HM the Queen of Denmark to Zagreb R&D Center of Excellence During State Visit to Croatia

Xellia Pharmaceuticals Seeks New Talent as it Expands Manufacturing Facility in Raleigh, NC

Xellia Pharmaceuticals Appoints Mads Bodenhoff as New Chief Financial Officer and Vice President

Xellia Pharmaceuticals Expands into the US with Acquisition of Manufacturing Plant

Xellia Pharmaceuticals Expands Croatian Product and Innovation R&D Centre of Excellence with Investment of US$2.0 million

Xellia Pharmaceuticals Appoints New Chairman and Board Members

Novo AS acquires Xellia Pharmaceuticals

Xellia Enters 4 Year Collaboration to Develop New Antibiotics to Combat Multi-Drug Resistant Bacteria